We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.33B
AUM Growth
-$428M
Cap. Flow
-$106M
Cap. Flow %
-2.44%
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
80
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$22.8M
2
XLO icon
Xilio Therapeutics
XLO
+$20.3M
3
AURA icon
Aura Biosciences
AURA
+$18M
4
CMPX icon
Compass Therapeutics
CMPX
+$17.7M
5
AGL icon
Agilon Health
AGL
+$10.2M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$49M
2
ALLK
Allakos
ALLK
+$32.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$26.3M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$20.9M
5
OSH
Oak Street Health, Inc.
OSH
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.41%
2 Consumer Staples 1.28%
3 Industrials 0.73%
4 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRTX
26
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$55.9M 1.29%
426,843
+34,926
+9% +$4.51M
FRPT icon
27
Freshpet
FRPT
$3.26B
$55.3M 1.28%
580,000
+53,000
+10% +$6.57M
ASND icon
28
Ascendis Pharma A/S
ASND
$16.8B
$53.8M 1.24%
400,000
– –
CERE
29
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$53.4M 1.23%
1,648,435
+47,846
+3% +$1.69M
IRTC icon
30
iRhythm Holdings
IRTC
$4.1B
$51M 1.18%
433,000
-15,000
-3% -$1.38M
KYMR icon
31
Kymera Therapeutics
KYMR
$9.03B
$47.1M 1.09%
742,065
+9,138
+1% +$532K
ACHC icon
32
Acadia Healthcare
ACHC
$2.96B
$45.4M 1.05%
748,500
+38,500
+5% +$2.3M
EXAS
33
DELISTED
Exact Sciences
EXAS
$44.4M 1.03%
570,000
– –
NVTA
34
DELISTED
Invitae Corporation
NVTA
$42.8M 0.99%
2,800,243
+194,414
+7% +$4.21M
PEN icon
35
Penumbra
PEN
$12.8B
$42.7M 0.99%
148,500
+1,000
+0.7% +$264K
SWAV
36
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$39.7M 0.92%
222,500
+2,500
+1% +$493K
SGEN
37
DELISTED
Seagen Inc. Common Stock
SGEN
$39.6M 0.91%
256,000
+6,000
+2% +$1M
SRPT icon
38
Sarepta Therapeutics
SRPT
$1.81B
$38.2M 0.88%
424,000
+74,000
+21% +$6.33M
ARVN icon
39
Arvinas
ARVN
$588M
$37.6M 0.87%
457,200
-120,300
-21% -$9.79M
WRBY icon
40
Warby Parker
WRBY
$3.26B
$33.7M 0.78%
724,000
+74,000
+11% +$3.85M
HCAT icon
41
Health Catalyst
HCAT
$127M
$33.7M 0.78%
850,200
+200
+0% +$9.12K
VERV
42
DELISTED
Verve Therapeutics
VERV
$33.3M 0.77%
902,926
-59,900
-6% -$2.52M
CVET
43
DELISTED
Covetrus, Inc. Common Stock
CVET
$33.2M 0.77%
1,661,700
+38,200
+2% +$719K
EHC icon
44
Encompass Health
EHC
$12.5B
$32.8M 0.76%
631,643
+3,143
+0.5% +$162K
PHR icon
45
Phreesia
PHR
$769M
$32.1M 0.74%
770,000
-200,000
-21% -$11.9M
PRTA icon
46
Prothena Corp
PRTA
$468M
$32M 0.74%
647,730
-62,700
-9% -$3.48M
ACCD
47
DELISTED
Accolade Inc
ACCD
$31.6M 0.73%
1,197,000
+274,000
+30% +$8.98M
DXCM icon
48
DexCom
DXCM
$33.1B
$30.5M 0.7%
227,000
+41,000
+22% +$5.89M
TVTX icon
49
Travere Therapeutics
TVTX
$5.74B
$29.5M 0.68%
951,650
-545,167
-36% -$15.4M
ABCM
50
DELISTED
Abcam PLC
ABCM
$29.5M 0.68%
1,252,500
+104,912
+9% +$2.35M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rock Springs Capital Management held 157 positions worth $4.33B, down 9% from $4.76B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2021 filing shows 4 new, 80 increased, 15 reduced and 21 closed positions. Its largest new stake was Xilio Therapeutics: 85,078 shares worth $19.1M. The largest sale was Teleflex, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2021 buy was Xilio Therapeutics: 85,078 shares worth $19.1M.
  • Rock Springs Capital Management added most to Baxter International in Q4 2021, an estimated $22.8M increase.
  • Rock Springs Capital Management's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Teleflex in Q4 2021, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $4.33B portfolio in Q4 2021.
  • Rock Springs Capital Management opened 4 new positions and closed 21 in Q4 2021.
  • Rock Springs Capital Management's portfolio value fell 9% quarter-over-quarter to $4.33B.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.